The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells

Neuro-Oncology

Volumn 13, Issue 9, 2011, Pages 1000-1010

  Oehlera, Christoph ^a   Von Buerena, André O ^b   Furmanovaa, Polina ^a   Broggini Tenzera, Angela ^a,c   Orlowski, Katrin ^a   Rutkowski, Stefan ^c   Frei, Karl ^a   Grotzer, Michael A ^b   Pruschy, Martin ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Apoptosis; Autophagy; Ionizing radiation; Medulloblastoma; Patupilone

Indexed keywords

CASPASE 3; EPOTHILONE B; PROTEIN P53; RADIOSENSITIZING AGENT; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; MEDULLOBLASTOMA; MOUSE; NONHUMAN; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY; EPOTHILONES; HUMANS; IMMUNOENZYME TECHNIQUES; MEDULLOBLASTOMA; MICE; MICE, NUDE; MICROTUBULES; MUTATION; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052770432     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor069     Document Type: Article

References (32)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl). 2007;114(2):97-109. (Pubitemid 47103521)
2. Kuhl J. Modern treatment strategies in medulloblastoma. Childs Nerv Syst. 1998;14(1-2):2-5. (Pubitemid 28269412)
3. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J Clin Oncol. 1999;17(7):2127-2136. (Pubitemid 29318845)
4. Reeves CB, Palmer SL, Reddick WE, et al. Attention and memory functioning among pediatric patients with medulloblastoma. J Pediatr Psychol. 2006;31(3):272-280.
5. Radcliffe J, Packer RJ, Atkins TE, et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with wholebrain radiotherapy. Ann Neurol. 1992;32(4):551-554.
6. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol. 1992;10(9):1390-1396. (Pubitemid 23059921)
7. Chapman CA, Waber DP, Bernstein JH, et al. Neurobehavioral and neurologic outcome in long-term survivors of posterior fossa brain tumors: role of age and perioperative factors. J Child Neurol. 1995;10(3):209-212.
8. Dennis M, Spiegler BJ, Hetherington CR, Greenberg ML. Neuropsychological sequelae of the treatment of children with medulloblastoma. J Neurooncol. 1996;29(1):91-101. (Pubitemid 26193508)
9. Packer RJ, Sutton LN, Goldwein JW, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg. 1991;74(3):433-440.
10. Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. Adult medulloblastoma: multiagent chemotherapy. Neuro Oncol. 2001;3(1):29-34. (Pubitemid 33685583)
11. von Bueren AO, von Hoff K, Benesch M, Rutkowski S. Dose reductions of vincristine in children with medulloblastoma treated in the maintenance arm of the prospective multicenter trial HIT'91. Klin Padiatr. 2009;221(6):396-397.
12. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17(3): 832-845. (Pubitemid 29109313)
13. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813-820. (Pubitemid 44464063)
14. Jakacki RBP, Zhou T, Holmes E, Packer RJ, Goldwein J, et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701. ASCO Annual Meeting Proceedings Part I, Journal of Clinical Oncology 2007.
15. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res. 2005;11(19 Pt 1):6950-6958. (Pubitemid 41428753)
16. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol. 2009;27(19):3097-3103.
17. Rothermel J,Wartmann M, Chen T, Hohneker J. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol. 2003;30(3 Suppl 6):51-55. (Pubitemid 36712859)
18. Bley CR, Jochum W, Orlowski K, et al. Role of the microenvironment for radiosensitization by patupilone. Clin Cancer Res. 2009;15(4): 1335-1342.
19. Hofstetter B, Vuong V, Broggini-Tenzer A, et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res. 2005;11(4):1588-1596. (Pubitemid 40315244)
20. Fogh S, Machtay M, Werner-Wasik M, et al. Phase I Trial Using Patupilone (Epothilone B) and Concurrent Radiotherapy for Central Nervous System Malignancies. Int J Radiat Oncol Biol Phys. 2010;77(4):1009-1016.
21. Saylors RL, 3rd, Sidransky D, Friedman HS, et al. Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 1991;51(17):4721-4723.
22. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000;1470(3):M79-91. (Pubitemid 30229922)
23. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928-942. (Pubitemid 38834285)
24. Sinclair WK. Cyclic x-ray responses in mammalian cells in vitro. Radiat Res. 1968;33(3):620-643.
25. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62(23):6938-6943. (Pubitemid 35424084)
26. Ferretti S, Allegrini PR, O'Reilly T, et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res. 2005;11(21):7773-7784. (Pubitemid 41611621)
27. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10(2):415-427. (Pubitemid 38173977)
28. Shen S, Kepp O, Martins I, et al. Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells. Cell Cycle. 2010;9(2):377-383.
29. Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude E, Blagosklonny MV. Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene. 2008;27(32):4402-4410.
30. von Bueren AO, Shalaby T, Oehler-Janne C, et al. RNA interferencemediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. BMC Cancer. 2009;9:10.
31. von Bueren AO, Shalaby T, Rajtarova J, et al. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer. 2007;7:19.
32. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004;11(4):448-457. (Pubitemid 38489422)